Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

"xn-person">Andrew R. Haas, M.D., Ph.D., Hospital of the University of Pennsylvania, and investigator on JX-594 Phase 1 trial.

This open-label, dose-escalation study was completed at four sites in the United States and Canada.  A total of 23 patients with solid tumors refractory to standard therapy were enrolled.  Patients received a single treatment at one of five dose levels, with follow-up at periodic intervals.  Six out of eight patients in the higher-dose cohorts evaluable to date (cohorts 3, 4, 5) exhibited disease control as defined by stable disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria and/or Choi (necrotic) response.  Two out of six patients in the low dose cohorts exhibited disease control (RECIST stable disease) but no responses.  The primary endpoints of the trial included safety and determination of the maximum tolerated dose given through intravenous administration.  No serious adverse events related to JX-594 therapy were reported and no dose-limiting toxicities were reported.  A biomarker analysis further strengthened the finding of dose-dependent replication in tumors following IV administration.

About JX-594

JX-594, currently in Phase 2 clinical trials for liver cancer, is a cancer biotherapeutic product from a proprietary breakthrough class of targeted and armed oncolytic and immunotherapeutic poxviruses.  Tumor destruction and safety was shown in patients with diverse cancer types in three Phase 1 trials; treated patients were end-stage and had no effective therapies available.  JX-594 multiplies selectively within cancer cells, leading to their destruction.  These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... August 23, 2014 Dr. ... LLC announced today that Janet B. Arrowsmith, MD, ... consultant. NDA Partners Premier Experts are top tier ... to bring extraordinary value to the company’s clients. ... solutions to help clients successfully develop their medical ...
(Date:8/22/2014)... August 23, 2014 This is ... state of the Papain industry in Global and ... the industry, including definitions, applications and industry chain ... analysis are provided with a focus on history, ... A comparison between the international and Chinese situation ...
(Date:8/22/2014)... August 22, 2014 Today the Academy of ... United States Court of Appeals for the D.C. Circuit challenging ... published in the Federal Register on June 25, 2014. ... contrary to the text and intent of the FAA Modernization ... Congress’ specific prohibition on any new rules or regulations regarding ...
(Date:8/22/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 2014.  Biorem,s complete 2014 second quarter financial statements and MD&A have been ... June 30, , Six-months ended June 30, ( in ... 2013 , 2014 , 2013 Revenue , ... 9,195 Gross profit , 56 , 1,485 , ...
Breaking Biology Technology:Noted Epidemiologist and Former FDA Deputy Director Janet B. Arrowsmith, MD, Joins NDA Partners as a Premier Expert Consultant 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3
... Accera Inc., a privately,held biotechnology company focused on ... it has appointed William,T. Poncy, M.B.A., as vice ... commercial launch of Ketasyn (AC-1202) as a medical ... Alzheimer,s disease. "Given his strong track record ...
... Assay Development, Biomarker Identification ... and ADME/Tox Applications, ... MCET), entered into a worldwide,exclusive license and technology purchase agreement ... human liver cell lines. Corning paid MultiCell a license ...
... Alliance, the leading,management consulting firm specializing in the pharmaceutical ... as one of the best,places to work in the ... Business Journal, ranking third among midsize companies. The award,was ... annual Best,Places to Work luncheon and awards ceremony on ...
Cached Biology Technology:Accera, Inc. Names William T. Poncy Vice President of Commercial Development 2Accera, Inc. Names William T. Poncy Vice President of Commercial Development 3MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 2MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 3Campbell Alliance Named 'Best Place to Work' by Triangle Business Journal 2
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... Markets ( http://www.researchandmarkets.com/research/mtm27l/biometrics_market ) has announced the ... North America 2014-2018"  report to their ... , , ,Biometrics is a technology ... individuals based on their physical or ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... the 29th Annual International Papillomavirus Conference shows that ... combats three types of human papillomavirus, including the ... cancer. , When tested in several cultured human ... HPV-18 and HPV-11 cells, according to Louise T. ... the findings at the Seattle conference. The National ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... 2013) The world,s leading conservation organizations have joined together ... eastern lowland gorilla ( Gorilla beringei graueri ). Found ... Democratic Republic of Congo (DRC), Grauer,s gorilla is not only ... largest primate in the world. With their entire range ...
... advance toward overcoming a major barrier to tapping the ... medicine in developing new and more effective modern drugs. ... Information and Modeling . Andreas Bender and ... modern medicine. In the world,s largest international clinical trial, ...
... World, the first international conference examining the critical link ... the University of Pennsylvania from Wednesday, March 13, through ... Penn Institute for Urban Research (Penn IUR), in partnership ... Steering Committee representing nine schools and six centers, is ...
Cached Biology News:Gorillas caught in the crossfire in the DRC 2Gorillas caught in the crossfire in the DRC 3Penn conference tackles complex relationship between urbanization and food 2
... Construction KitTM allows graphic manipulation of DNA ... has an award winning interface design that ... addition to providing sophisticated drawing capabilities for ... the "Best Plasmid Mapping Software" by the ...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
...
...
Biology Products: